The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ...

STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma ...

Leading Malignant Pleural Effusion companies in the market include - RS Oncology, Genelux Corporation, Candel Therapeutics, and others. The Malignant Pleural Effusion Market is projected to experience ...

Please provide your email address to receive an email when new articles are posted on . The addition of durvalumab to chemotherapy appeared to confer a significant OS benefit as initial treatment for ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

Phase II, open-label study of erlotinib (ERL) in patients with NSCLC with activating mutations of the EGFR identified on tissue samples, plasma DNA, and CTC-trigger. This is an ASCO Meeting Abstract ...

Clinicians frequently rely on expert opinions, which are sometimes later disproven by randomised controlled trials (RCTs). For example, intrapleural streptokinase was commonplace until the MIST-1 ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line ...

A 66-year-old woman presented for evaluation after developing effusion around her left lung. She had been diagnosed previously with extensive-stage small-cell lung cancer, which was treated. The ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that results from the STELLAR trial were published in The Lancet Oncology. The STELLAR trial was a prospective, single-arm ...